Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Headquartered in Westlake Village, California, the company's mission is to champion meaningful innovation to address urgent unmet needs in conditions affecting the skin, aiming to improve patient outcomes through differentiated therapies.

The company's key product is ZORYVE (roflumilast) cream, a topical phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis and atopic dermatitis across various age groups. Arcutis also offers ZORYVE foam for conditions such as seborrheic dermatitis and scalp and body psoriasis. Its pipeline includes ARQ-234, a fusion protein acting as a checkpoint agonist of the CD200 receptor, and topical JAK1 inhibitor formulations, targeting a range of inflammatory dermatological conditions including alopecia areata.

Led by President and CEO Frank Watanabe, Arcutis operates as a fully commercial-stage organization with multiple FDA approvals and a robust pipeline. The leadership team brings extensive dermatology expertise, having collectively contributed to over 50 FDA-approved products. Recent notable activities include reporting Q1 2026 financial results, with ZORYVE generating $105.4 million in net product revenue, and submitting a supplemental New Drug Application (sNDA) to the FDA to expand the indication for ZORYVE cream 0.05% for atopic dermatitis in infants aged 3-24 months. The company is positioned as an emerging leader in the medical dermatology market.